OBJECTIVE: Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES. METHODS: A retrospective analysis of the three participating institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of the participating institutions between 1989 and 2012. Of this group, 17 patients received chemotherapy. RESULTS: Patients' median overall survival (OS) after the beginning of palliative chemotherapy was 21 months, and the 1-year OS was 87%. Twelve patients received Gem/Doce with a clinical benefit rate of 83%. The median progression-free survival (PFS) was 8 months for all patients receiving Gem/Doce. The best response was complete remission in 1 patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line treatment showed measurable responses with a median PFS of 9 months. CONCLUSIONS: In this retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospective studies are needed to better assess the effects of this combination drug therapy.
OBJECTIVE:Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES. METHODS: A retrospective analysis of the three participating institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of the participating institutions between 1989 and 2012. Of this group, 17 patients received chemotherapy. RESULTS:Patients' median overall survival (OS) after the beginning of palliative chemotherapy was 21 months, and the 1-year OS was 87%. Twelve patients received Gem/Doce with a clinical benefit rate of 83%. The median progression-free survival (PFS) was 8 months for all patients receiving Gem/Doce. The best response was complete remission in 1 patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line treatment showed measurable responses with a median PFS of 9 months. CONCLUSIONS: In this retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospective studies are needed to better assess the effects of this combination drug therapy.
Authors: Anna Maria Frezza; Robin L Jones; Salvatore Lo Vullo; Naofumi Asano; Francesca Lucibello; Eytan Ben-Ami; Ravin Ratan; Pawel Teterycz; Kjetil Boye; Mehdi Brahmi; Emanuela Palmerini; Alexander Fedenko; Bruno Vincenzi; Antonella Brunello; Ingrid M E Desar; Robert S Benjamin; Jean Yves Blay; Javier Martin Broto; Paolo G Casali; Hans Gelderblom; Giovanni Grignani; Alessandro Gronchi; Kirsten Sundby Hall; Olivier Mir; Piotr Rutkowski; Andrew J Wagner; Olga Anurova; Paola Collini; Angelo P Dei Tos; Uta Flucke; Jason L Hornick; Ingvild Lobmaier; Terrier Philippe; Piero Picci; Dominique Ranchere; Salvatore L Renne; Marta Sbaraglia; Khin Thway; Michal Wagrodzki; Wei-Lien Wang; Akihiko Yoshida; Luigi Mariani; Akira Kawai; Silvia Stacchiotti Journal: JAMA Oncol Date: 2018-09-13 Impact factor: 31.777
Authors: Sheri L Spunt; Nadine Francotte; Gian Luca De Salvo; Yueh-Yun Chi; Ilaria Zanetti; Andrea Hayes-Jordan; Simon C Kao; Daniel Orbach; Bernadette Brennan; Aaron R Weiss; Max M van Noesel; Lynn Million; Rita Alaggio; David M Parham; Anna Kelsey; R Lor Randall; M Beth McCarville; Gianni Bisogno; Douglas S Hawkins; Andrea Ferrari Journal: Eur J Cancer Date: 2019-04-05 Impact factor: 9.162
Authors: Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller Journal: Front Oncol Date: 2015-08-17 Impact factor: 6.244
Authors: Yunjung Choi; Mi Sun Yun; Sang Hee Lim; Jeeyun Lee; Jin-Hee Ahn; Yu Jung Kim; Kyong Hwa Park; Young Suk Park; Ho Yeong Lim; Hyonggin An; Dong-Churl Suh; Yeul Hong Kim Journal: Cancer Res Treat Date: 2017-03-30 Impact factor: 4.679
Authors: Anneke Alves; Anastasia Constantinidou; Khin Thway; Cyril Fisher; Paul Huang; Robin L Jones Journal: Eur J Cancer Care (Engl) Date: 2021-07-18 Impact factor: 2.328